← Human Trials & Peer-Reviewed Studies
Comparison Between Beta-Blockers with Angiotensin-Converting Enzyme Inhibitors and Beta-Blockers with Angiotensin II Type I Receptor Blockers in ST-Segment Elevation Myocardial Infarction After Successful Percutaneous Coronary Intervention with Drug-Eluting Stents.
Plain-language guide to PMID 30632033 (2019): observational study of Angiotensin II in 13,873 patients.
Key Facts
- PMID
- 30632033
- Journal
- Cardiovascular drugs and therapy
- Year
- 2019
- Study type
- Observational Study
- Authors
- Kim YH et al. (12 authors)
- DOI
- 10.1007/s10557-018-6841-7
What This Study Did, in Plain Language
What Was Tested
Researchers studied Angiotensin II in this observational study publication.
Limited comparative data concerning long-term clinical outcomes of combination therapy between beta-blockers (BB) with angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) therapy in patients with ST-segment elevation myocardial infarction (STEMI) are available.
The researchers thought to compare 2-year major clinical outcomes between BB with ACEI and BB with ARB therapy in patients with STEMI after successful percutaneous coronary intervention (PCI) with drug-eluting stents (DES).
Who Took Part
According to the abstract, 13,873 patients were involved.
PubMed indexes the participants as middle-aged adults and older adults, both men and women.
13,873 STEMI patients who underwent successful PCI with DES were enrolled and divided into two groups as the BB with ACEI group (n = 10,393) and the BB with ARB group (n = 3480).
What Was Measured
The subject headings attached to it are Adrenergic beta-Antagonists, Angiotensin II Type 1 Receptor Blockers, Angiotensin-Converting Enzyme Inhibitors, Coronary Angiography, Drug-Eluting Stents, Percutaneous Coronary Intervention and Recurrence.
The authors tagged it with the keywords Angiotensin receptor blocker, Beta-blocker and Myocardial infarction.
What This Means in Plain Language
This is an observational study of Angiotensin II in 13,873 patients.
With several hundred people or more, it is a fairly large study for this kind of research.
Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2019 (Cardiovascular drugs and therapy), a journal based in United States.
More context: the Angiotensin II compound page, all human trials.
Our Notes on the Compound
Angiotensin II: An 8-amino-acid hormone that narrows blood vessels; synthetic angiotensin II (Giapreza) is used for low blood pressure in shock.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.